As of today, there are two US FDA‐approved immune checkpoint inhibitors targeting PD‐1 for use in dMMR and MSI‐H advanced CRC patients who have failed the first‐line therapy [264]. This evidence concerns the gene PDCD1 and colorectal carcinoma.